Literature DB >> 3162101

Retinoic acid embryopathy.

E J Lammer, D T Chen, R M Hoar, N D Agnish, P J Benke, J T Braun, C J Curry, P M Fernhoff, A W Grix, I T Lott.   

Abstract

Retinoic acid, an analogue of vitamin A, is known to be teratogenic in laboratory animals and has recently been implicated in a few clinical case reports. To study the human teratogenicity of this agent, we investigated 154 human pregnancies with fetal exposure to isotretinoin, a retinoid prescribed for severe recalcitrant cystic acne. The outcomes were 95 elective abortions, 26 infants without major malformations, 12 spontaneous abortions, and 21 malformed infants. A subset of 36 of the 154 pregnancies was observed prospectively. The outcomes in this cohort were 8 spontaneous abortions, 23 normal infants, and 5 malformed infants. Exposure to isotretinoin was associated with an unusually high relative risk for a group of selected major malformations (relative risk = 25.6; 95 per cent confidence interval, 11.4 to 57.5). Among the 21 malformed infants we found a characteristic pattern of malformation involving craniofacial, cardiac, thymic, and central nervous system structures. The malformations included microtia/anotia (15 infants), micrognathia (6), cleft palate (3), conotruncal heart defects and aortic-arch abnormalities (8), thymic defects (7), retinal or optic-nerve abnormalities (4), and central nervous system malformations (18). The pattern of malformation closely resembled that produced in animal studies of retinoid teratogenesis. It is possible that a major mechanism of isotretinoin teratogenesis is a deleterious effect on cephalic neural-crest cell activity that results in the observed craniofacial, cardiac, and thymic malformations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3162101     DOI: 10.1056/NEJM198510033131401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  305 in total

1.  Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program.

Authors:  G Atanackovic; G Koren
Journal:  CMAJ       Date:  1999-06-15       Impact factor: 8.262

Review 2.  Clusters of birth defects: emergency and management. A review of some publications.

Authors:  J Goujard
Journal:  Eur J Epidemiol       Date:  1999-10       Impact factor: 8.082

Review 3.  Drug-induced congenital defects: strategies to reduce the incidence.

Authors:  M De Santis; B Carducci; A F Cavaliere; L De Santis; G Straface; A Caruso
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  Multiple hits during early embryonic development: digenic diseases and holoprosencephaly.

Authors:  Jeffrey E Ming; Maximilian Muenke
Journal:  Am J Hum Genet       Date:  2002-10-22       Impact factor: 11.025

5.  Close linkage of retinoic acid receptor genes with homeobox- and keratin-encoding genes on paralogous segments of mouse chromosomes 11 and 15.

Authors:  J H Nadeau; J G Compton; V Giguère; J Rossant; S Varmuza
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

6.  Migration of cranial neural crest cells to the pharyngeal arches and heart in rat embryos.

Authors:  Y Fukiishi; G M Morriss-Kay
Journal:  Cell Tissue Res       Date:  1992-04       Impact factor: 5.249

7.  Generic isotretinoin: a new risk for unborn children.

Authors:  Gideon Koren; Marina Avner; Neil Shear
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

8.  Retinoic acid repression of bone morphogenetic protein 4 in inner ear development.

Authors:  Deborah L Thompson; Lisa M Gerlach-Bank; Kate F Barald; Ronald J Koenig
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

9.  Phase II trial of beta-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap.

Authors:  V Graham; E S Surwit; S Weiner; F L Meyskens
Journal:  West J Med       Date:  1986-08

10.  Retinoic acid uses divergent mechanisms to activate or suppress mitogenesis in rat aortic smooth muscle cells.

Authors:  S Chen; D G Gardner
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.